PolyPeptide Group AG
SIX:PPGN.SW
32.15 (CHF) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) CHF.
| 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | 2018 Q4 | 2018 Q3 | 2018 Q2 | 2018 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 188.538 | 131.834 | 147.322 | 133.656 | 146.99 | 135.136 | 135.869 | 88.427 | 50.653 | 50.653 | 50.653 | 50.653 | 44.894 | 44.894 | 44.894 | 44.894 |
| Cost of Revenue
| 181.093 | 134.506 | 132.211 | 96.776 | 95.587 | 86.839 | 86.781 | 64.327 | 32.76 | 32.76 | 32.76 | 32.76 | 29.363 | 29.363 | 29.363 | 29.363 |
| Gross Profit
| 7.445 | -2.672 | 15.111 | 36.88 | 51.403 | 48.297 | 49.088 | 24.1 | 17.894 | 17.894 | 17.894 | 17.894 | 15.531 | 15.531 | 15.531 | 15.531 |
| Gross Profit Ratio
| 0.039 | -0.02 | 0.103 | 0.276 | 0.35 | 0.357 | 0.361 | 0.273 | 0.353 | 0.353 | 0.353 | 0.353 | 0.346 | 0.346 | 0.346 | 0.346 |
| Reseach & Development Expenses
| 0.719 | 0.746 | 0.587 | 0.656 | 0.711 | 0.696 | 0.713 | 0.599 | 3.594 | 3.594 | 3.594 | 3.594 | 3.077 | 3.077 | 3.077 | 3.077 |
| General & Administrative Expenses
| 16.901 | 19.097 | 15.436 | 19.107 | 15.697 | 11.88 | 12.208 | 11.55 | 2.577 | 2.577 | 2.577 | 2.577 | 2.497 | 2.497 | 2.497 | 2.497 |
| Selling & Marketing Expenses
| 2.06 | 1.993 | 2.316 | 2.589 | 1.731 | 2.133 | 1.849 | 1.791 | 0.309 | 0.309 | 0.309 | 0.309 | 0.329 | 0.329 | 0.329 | 0.329 |
| SG&A
| 20.446 | 21.09 | 18.931 | 21.696 | 18.485 | 14.013 | 14.672 | 13.341 | 2.886 | 2.886 | 2.886 | 2.886 | 2.826 | 2.826 | 2.826 | 2.826 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -15.986 | -15.986 | -15.986 | -15.986 | -14.494 | -14.494 | -14.494 | -14.494 |
| Operating Expenses
| 25.655 | 31.792 | 20.944 | 21.398 | 19.543 | 17.494 | 18.354 | 13.94 | -9.506 | -9.506 | -9.506 | -9.506 | -8.591 | -8.591 | -8.591 | -8.591 |
| Operating Income
| -10.865 | -22.964 | -2.955 | 15.482 | 30.877 | 36.524 | 34.151 | 10.16 | 8.387 | 8.387 | 8.387 | 8.387 | 6.94 | 6.94 | 6.94 | 6.94 |
| Operating Income Ratio
| -0.058 | -0.174 | -0.02 | 0.116 | 0.21 | 0.27 | 0.251 | 0.115 | 0.166 | 0.166 | 0.166 | 0.166 | 0.155 | 0.155 | 0.155 | 0.155 |
| Total Other Income Expenses Net
| -8.151 | -16.263 | -2.319 | -2.641 | -0.556 | -6.997 | -5.766 | -0.86 | -0.829 | -0.829 | -0.829 | -0.829 | 0.424 | 0.424 | 0.424 | 0.424 |
| Income Before Tax
| -19.016 | -39.227 | -5.274 | 12.841 | 30.321 | 29.527 | 28.385 | 9.3 | 7.558 | 7.558 | 7.558 | 7.558 | 7.364 | 7.364 | 7.364 | 7.364 |
| Income Before Tax Ratio
| -0.101 | -0.298 | -0.036 | 0.096 | 0.206 | 0.218 | 0.209 | 0.105 | 0.149 | 0.149 | 0.149 | 0.149 | 0.164 | 0.164 | 0.164 | 0.164 |
| Income Tax Expense
| 1.842 | 4.961 | 2.794 | 2.594 | 7.686 | 4.904 | 4.881 | 1.469 | 1.124 | 1.124 | 1.124 | 1.124 | 1.409 | 1.409 | 1.409 | 1.409 |
| Net Income
| -17.174 | -34.266 | -2.48 | 10.247 | 22.635 | 24.623 | 23.504 | 7.831 | 6.434 | 6.434 | 6.434 | 6.434 | 5.955 | 5.955 | 5.955 | 5.955 |
| Net Income Ratio
| -0.091 | -0.26 | -0.017 | 0.077 | 0.154 | 0.182 | 0.173 | 0.089 | 0.127 | 0.127 | 0.127 | 0.127 | 0.133 | 0.133 | 0.133 | 0.133 |
| EPS
| -0.52 | -1.04 | -0.075 | 0.31 | 0.68 | 0.79 | 0.78 | 0.26 | 0.21 | 0.21 | 0.21 | 0.21 | 0.2 | 0.2 | 0.2 | 0.2 |
| EPS Diluted
| -0.52 | -1.04 | -0.075 | 0.31 | 0.68 | 0.79 | 0.78 | 0.26 | 0.21 | 0.21 | 0.21 | 0.21 | 0.2 | 0.2 | 0.2 | 0.2 |
| EBITDA
| -2.422 | -9.887 | 6.347 | 26.706 | 37.846 | 45.61 | 39.303 | 19.134 | 8.783 | 8.783 | 8.783 | 8.783 | 8.921 | 8.921 | 8.921 | 8.921 |
| EBITDA Ratio
| -0.013 | -0.075 | 0.043 | 0.2 | 0.257 | 0.338 | 0.289 | 0.216 | 0.173 | 0.173 | 0.173 | 0.173 | 0.199 | 0.199 | 0.199 | 0.199 |